Skip to main navigation
Kyverna Therapeutics Logo
  • Overview
  • News Releases
  • Events & Presentations
  • Governance
    • Governance Overview
    • Board of Directors
    • Leadership Team
    • Committee Composition
  • Financials
    • SEC Filings
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR
    • Educational Videos

Investor Relations

Minimum 15 minutes delayed. Source: LSEG

Our Mission

Our Mission

Liberating autoimmune patients through the curative potential of cell therapy.

Read More
Kyverna

Corporate Presentation

Positive Longer-Term Durability and Safety Data of Miv-cel in SPS and gMG

Investor Presentation - September 2026

Kyverna AAN Conference Call Presentation

KYSA-8 Topline Results for Stiff Person Syndrome

Educational Videos

Expand your knowledge about CAR T-cell therapies and autoimmune diseases from scientist and patient perspectives. View here

News Releases

Press Releases

September 24, 2026
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
September 2, 2026
Kyverna Therapeutics to Present at Upcoming Investor Conferences
September 1, 2026
Company Statement on Miv-cel's Favorable Safety Profile
August 11, 2026
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
View All News

Investor Contact

drafts InvestorRelations@kyvernatx.com
drafts Media@kyvernatx.com
phone_iphone +1 510.925.2492
© 2026 Kyverna Therapeutics

Social Media

  • LinkedIn opens in new window
  • Glassdoor opens in new window
Search Investors